© с сайта Томского госуниверситета
TOMSK, Sep 5 – RIA Tomsk. Scientists of Tomsk State University
(TSU) and Tomsk National Research Medical Center (NRMC) together with
colleagues from Germany and Latvia are creating a new way of treating of
oncological diseases, in which tumor microenvironment cells will impede its
development, the press service of the university reports on Tuesday.
It is explained that the research of a world oncology is aimed at finding
opportunities to kill a tumor cell, which does not always lead to regression of
the tumor. Tomsk scientists and colleagues from Heidelberg University and
Latvian Biomedical Research and Study Centre are developing a new approach. Its
essence – is in the impact on the tumor microenvironment cells, which can
hinder the development of oncology.
According to the head of the laboratory of molecular oncology and immunology of
the National Research Medical Center (NRMC), the leading researcher of the
laboratory of translational cellular and molecular biomedicine TSU Nadezhda
Cherdyntseva, macrophages are one of the key elements of tumor microenvironment
regulation.
"Tumor cells are able to program them (macrophages) for interaction. In
that case macrophages "work" to maintain the progression of the
tumor. But potentially these cells have all the necessary functions to prevent
the growth of the tumor and its ability to metastasize", – Cherdyntseva is
quoted.
© РИА Томск. Яна Кузьминых
It is specified that as a tool for influencing macrophages scientists intend to
use stabilin – bound chitinase-like protein discovered by scientists earlier.
It suppresses the ability of macrophages to help a tumor grow.
It is added that a new therapeutic approach will be developed and will undergo
preclinical trials until the end of 2018. In the future, researchers from
Russia, Germany and Latvia are going to file a joint application for funding
clinical research within the framework of the European Union's Horizont 2020
program. A new way to treat oncological diseases can be used alone or in
combination with chemotherapy.